Scholar Rock Holding Corporation SRRK
43.21 USD +0.05 (+0.10%)
At closeNov 13, 2026, 4:00 PM EST
43.21 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
42.76 Day range 44.16
34.25 52-week range 61.76
- YTD
- -1.92%
- 1 year
- +43.68%
News
businesswire.com Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 39,587 shares of its common…
benzinga.com Wolfe Research Downgrades Scholar Rock Holding to Peer Perform Wolfe Research analyst Kalpit Patel downgrades Scholar Rock Holding (NASDAQ:SRRK) from Outperform to Peer Perform.
marketbeat.com What Scholar Rock (SRRK) Said on Its Q3 Earnings Call Scholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and…
seekingalpha.com Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
benzinga.com Scholar Rock Holding Q3 2026 Earnings Call Transcript Scholar Rock Holding (NASDAQ:SRRK) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.
benzinga.com BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future…- benzinga.com Scholar Rock Holding Q3 EPS $(0.81) Beats $(0.85) Estimate, Sales $600.000K Beat $22.429K Estimate Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 10 percent increase over losses of…
businesswire.com Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
gurufocus.com Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets
businesswire.com Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common…
benzinga.com Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading…
businesswire.com Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
defenseworld.net Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares…
benzinga.com Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
prnewswire.com Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK)…- benzinga.com Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77 Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
businesswire.com Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common…
benzinga.com JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70 JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
defenseworld.net Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure…
seekingalpha.com Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with…
benzinga.com Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72 Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $65 to $72.
benzinga.com Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75 Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $60 to $75.- benzinga.com Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65 Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $57 to $65.
benzinga.com This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.- benzinga.com Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70 Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $64 to $70.
benzinga.com Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM Energy and Paymentus; Agilon upgraded to Outperform.
benzinga.com Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58 Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Equal-Weight and raises the price target from $55 to $58.
247wallst.com Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded,…- benzinga.com HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $65 to $70.
seekingalpha.com Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript- benzinga.com Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72 Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy and raises the price target from $65 to $72.
- benzinga.com BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84 BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $76 to $84.
- benzinga.com Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76 Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $76.
benzinga.com Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74 Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $60 to $74.
benzinga.com Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years…
benzinga.com Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients two years and older.- benzinga.com Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
reuters.com Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
businesswire.com Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular…
reuters.com US FDA approves Scholar Rock's muscle weakness drug The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness.- benzinga.com HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
- benzinga.com Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
benzinga.com Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026 FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time…- benzinga.com JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63 JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
benzinga.com Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.- benzinga.com Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.